#AUTL hashtag - Bluesky

Trade Alerts, Monday January 12, 2026 – Crystal Equity Research

2 months ago

Small-cap stocks with declining money flow, Mon Jan 12th - #TLS #STKL #SEPN #RBBN #PRQR #OM #NWL #NAGE #MDWD #IART #HNRG #GEMI #FCCO #EQ #DOMO #CLNN #BTBT #AUTL #SI #OPFI #JBI #CPF #CDRE #AHT - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform Autolus (NASDAQ: AUTL) will evaluate Cellares’ fully automated Cell Shuttle platform to complement commercial manufacturing of AUCATZYL® (obe-cel) at its Nucleus facility in Stevenage, UK.The Cell Shuttle integrates CAR T unit operations in a single-use cartridge and can process up to 16 patient batches in parallel, with an architecture Cellares says can deliver up to 10-fold higher throughput versus conventional facilities. Cellares pairs this with Cell Q for automated, high-throughput QC and holds the FDA AMT designation.

2 months ago

#AUTL Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

www.stocktitan.net/news/AUTL/autolus-therap...

0 0 0 0

Most Searched, Tuesday November 25, 2025 – Crystal Equity Research

4 months ago

Most searched small-cap stocks, Tue Nov 25th - #DVLT #AEHL #WRD #WOOF #UUUU #SRPT #SGBX #RVT #RAMP #PEBO #ONDS #MGNX #LAC #CLSK #CETY #CERS #CAAS #BORR #AUTL #ALLO - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Trade Alerts, Tuesday November 25, 2025 – Crystal Equity Research

4 months ago

Small-cap stocks gapping up in trading, Tue Nov 25th - #HSAI #CETY #SAVA #IMMR #ESPR #AUTL #ZIM #SEM #OPTU #KSS #BNED - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates Autolus Therapeutics (Nasdaq: AUTL) reported Q3 2025 results and operational updates on Nov 12, 2025. Key commercial metrics: Q3 net product revenue $21.1M, deferred revenue $7.6M, and 60 U.S. treatment centers activated as of Nov 12, 2025. Cash and marketable securities totaled $367.4M at Sept 30, 2025.Clinical highlights include rmAT designation for obe-cel in pediatric r/r B-ALL, CARLYSLE Phase 1 data in severe refractory SLE showing DORIS remission in 83% (5/6) and CRR in 50% (3/6), and first patient dosed in a progressive MS Phase 1 trial. Management additions announced to support commercialization and manufacturing.

4 months ago

#AUTL Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

www.stocktitan.net/news/AUTL/autolus-therap...

0 0 0 0

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025 Autolus Therapeutics (NASDAQ: AUTL)50x10^6 cells (±20%) with median follow-up of 8.9 months (range 6.0–13.8).Key findings: no DLTs, no ICANS, no Grade ≥2 CRS; remission by DORIS in 83.3% (5/6); complete renal response in 50% (3/6); all patients tapered steroids to ≤5 mg/day; deep B-cell depletion followed by naïve B-cell reconstitution. Company expects to dose first Phase 2 LN patient before year-end 2025 and reports alignment with the FDA on trial design.

5 months ago

#AUTL Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

www.stocktitan.net/news/AUTL/autolus-therap...

0 0 0 0

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates Autolus Therapeutics (NASDAQ:AUTL) reported Q2 2025 financial results, highlighting $20.9 million in AUCATZYL® net product revenue and $29.9 million for H1 2025. The company received conditional marketing authorizations from both UK MHRA and European Commission for AUCATZYL®. Key developments include 46 activated U.S. centers and coverage for >90% of U.S. medical lives.Updated FELIX trial data showed promising 42.5-month median duration of response for obe-cel in r/r B-ALL, with 38.4% of responders maintaining remission. The company plans to initiate Phase 2 pivotal trial in lupus nephritis and Phase 1 trial in progressive MS by year-end 2025.Financial position remains strong with $454.3 million in cash and equivalents. Q2 2025 net loss was $47.9 million ($0.18 per share), compared to $58.3 million ($0.22 per share) in Q2 2024. ["Q2 2025 AUCATZYL® net product revenue reached $20.9 million", "Coverage secured for over 90% of U.S. medical lives", "Strong cash position of $454.3 million", "Received EU and UK conditional marketing authorizations", "Promising 42.5-month median duration of response in FELIX trial", "46 fully activated centers in U.S.", "Net loss decreased to $47.9M from $58.3M year-over-year"]

7 months ago

#AUTL Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

www.stocktitan.net/news/AUTL/autolus-therap...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Small-cap stocks overbought with declining relative strength, Thu Jun 12th- #CTEV #KAR #LVWR #AUTL #CTRN #ENTA #IMRX #LOOP #TDUP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 1 0 0

CaptainCraybeard

@captaincraybeard.bsky.social

9 months ago

Anchors down at the island! Standard Adventure kits + Shipshape Island kits (including the new snake and turtle heads and shell!) for your Mischievers! Coming to CAPPYSPACE.com Fri 6/13 9pm EDT #mischievers #draga #rawnha #autl #scute #islandkit #adventurekit #cappyspace #biomasters #glyos

5 2 1 0

Breakthrough Clinical Data: Autolus' Obe-cel Achieves 40% Sustained Remission in Adult B-ALL Patients Without Transplant New clinical data reveals Obe-cel's potential as definitive B-ALL treatment, with 40% sustained remission rate and positive outcomes across age groups. See full results.

10 months ago

#AUTL Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

www.stocktitan.net/news/AUTL/autolus-therap...

1 0 0 0

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates Autolus Therapeutics reported Q1 2025 financial results and key business updates. The company achieved $9.0 million in net product revenue from AUCATZYL®. Notable developments include UK MHRA's conditional marketing authorization for AUCATZYL® for treating adult r/r B-ALL patients. The company has 39 activated centers in the U.S. with coverage for ~90% of U.S. medical lives. Preliminary data from the Phase 1 CARLYSLE trial in SLE showed promising results, with plans for Phase 2 pivotal trials in lupus nephritis and Phase 1 trials in MS by year-end 2025. Financial results show a net loss of $70.2 million for Q1 2025, with cash reserves of $516.6 million. Operating expenses increased due to commercialization activities, with R&D expenses at $26.7 million and SG&A expenses at $29.5 million.

10 months ago

#AUTL Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

www.stocktitan.net/news/AUTL/autolus-therap...

0 0 0 0

Autolus Clinical Trial Shows Breakthrough 50% Response in Lupus Patients, Plans MS Treatment Launch Early trial reveals 50% complete renal response in lupus patients. Autolus expands into multiple sclerosis with new trial planned. See full pipeline details.

11 months ago

#AUTL Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

www.stocktitan.net/news/AUTL/autolus-therap...

0 0 0 0

Autolus Triples Cash to $588M, Secures 85% Coverage for FDA-Approved AUCATZYL Autolus reports robust $588M cash position while AUCATZYL commercial rollout accelerates with 33 treatment centers and 85% US coverage secured post-FDA approval.

1 year ago

#AUTL Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

www.stocktitan.net/news/AUTL/autolus-therap...

0 0 0 0

Autolus' AUCATZYL Shows Superior Cost-Effectiveness and 84% Deep Remission Rate in Latest Data New data reveals AUCATZYL therapy achieves better outcomes with lower adverse event costs vs other CAR-T treatments. Study shows 84% of responders reach deep molecular remission.

1 year ago

#AUTL Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

www.stocktitan.net/news/AUTL/autolus-therap...

0 0 0 0

Autolus Therapeutics Provides Business Updates and 2025 Overview Autolus Therapeutics (Nasdaq: AUTL) has provided significant business updates and an overview of its 2025 milestones. The company is actively progressing with the commercial launch of AUCATZYL® (obecabtagene autoleucel or 'obe-cel'), with 24 treatment centers fully authorized as of January 10th, 2025, and plans to reach 30 centers by the end of January 2025 and 60 by the end of the year.Notably, the National Comprehensive Cancer Network® (NCCN) has included AUCATZYL® in its Clinical Practice Guidelines in Oncology for treating adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). This endorsement follows FDA approval on November 8, 2024, and publication of the FELIX trial data in the New England Journal of Medicine.Autolus plans to expand its clinical development program into autoimmune diseases, with initial data from the CARLYSLE Phase 1 trial in systemic lupus erythematosus (SLE) expected in Q1 2025. The company will provide further updates at an R&D investor event on April 23, 2025, in New York City.Marketing authorization submissions for obe-cel are under regulatory review in the European Union and the United Kingdom, with potential approvals expected in the second half of 2025. Other anticipated milestones include initial data from the PY01 trial in pediatric ALL and a Phase 1 SLE trial presentation at a medical conference in H2 2025.

1 year ago

#AUTL Autolus Therapeutics Provides Business Updates and 2025 Overview

www.stocktitan.net/news/AUTL/autolus-therap...

0 0 0 0